Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

Published:2020-01 Issue:1 Volume:18 Page:69-81.e3
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Singh Siddharth^ORCID,Facciorusso Antonio,Dulai Parambir S.,Jairath Vipul,Sandborn William J.

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Institutes of Health

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference42 articles.

1. Annual burden and costs of hospitalization for high-need, high-cost patients with chronic gastrointestinal and liver diseases;Nguyen;Clin Gastroenterol Hepatol,2018

2. Infections and cardiovascular complications are common causes for hospitalization in older patients with inflammatory bowel diseases;Nguyen;Inflamm Bowel Dis,2018

3. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREATTM registry;Lichtenstein;Am J Gastroenterol,2012

4. Crohn's disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab;Osterman;Am J Gastroenterol,2016

5. Infectious and malignant complications of TNF inhibitor therapy in IBD;Targownik;Am J Gastroenterol,2013

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tuberculosis risk in patients with Crohn’s disease on biologics: a retrospective analysis of the Japanese Medical Claims Database;Intestinal Research;2024-08-19

2. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

3. Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers;American Journal of Gastroenterology;2024-07-12

4. Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review);Koloproktologia;2024-06-21

5. Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach;Drug Development Research;2024-06